Forgo Compensation. Each Non-Employee Director will be eligible to forgo all or a portion of his or her Board Compensation for any Term. Elections with respect to any Term must be made in writing to the Company prior to the start of such Term and all such elections will be irrevocable.

In light of the global COVID-19 pandemic, Executive volunteered to forgo 100% of his base salary from April 1, 2020 until May 31, 2020 and the Board of Directors of the Company agreed to reduce his compensation accordingly.

The Parties forgo a probationary period.

Compensation. FibroGen will pay you a starting annual salary of $500,000, payable in semi-monthly installments on our regular paydays in accordance with FibroGen's standard payroll policies. Your salary will begin as of the Effective Date. The position is classified as exempt and therefore not eligible for overtime pay. The first and last payment by FibroGen to you will be adjusted, if necessary, to reflect a commencement or termination date other than the first or last working day of a pay period.

Compensation. In exchange for the timely completion of Services during the Term, [[Agenus:Organization]] shall pay Consultant a retainer of $10,000 per month. All payments shall be made to Consultant within thirty (30) days after the last day of each calendar month during the Term without the need for an invoice. The total Fees during the Term shall not exceed $120,000 without amendment to this Agreement. All compensation and expense reimbursements to be paid under this Agreement shall be paid to Consultant in U.S. Dollars. Consultant acknowledges and agrees that payments made hereunder are for Services performed by Consultant. No payments shall be passed through to third parties on behalf of [[Agenus:Organization]] without a valid invoice or other written documentation between the Parties evidencing such payment arrangement.

Compensation. The Company shall grant to Consultant an option to purchase 200,000 shares of the Company’s Common Stock at an exercise price per share equal to the closing price of the Company’s Common Stock on such date (the “Stock Options”), and such options will vest in equal quarterly installments beginning three months from the date of grant. Notwithstanding the foregoing, upon the consummation of a Change in Control, the then remaining unvested portion of the Option shall immediately vest and become fully exercisable. "Change in Control" is defined in the Plan.

Compensation. Any officer, employee, independent contractor, consultant or agent of the Seller will be compensated from the Seller’s funds for services provided to the Seller, and to the extent that Seller shares the same officers, employees, independent contractors, consultants or agents as the Master Servicer (or any other Affiliate thereof), the salaries, fees, costs and expenses relating to such Persons shall be fairly allocated among such entities, and each such entity shall bear its fair share of the salary and benefit costs associated with such common officers, employees, independent contractors, consultants and agents. The Seller will not engage any agents other than its attorneys, auditors and other professionals, and a servicer and any other agent contemplated by the Facility Documents for the Receivables Pool, which servicer will be fully compensated for its services by payment of the Servicing Fee.

Compensation. As consideration for Advisor’s Services, the Company will pay to Advisor a quarterly retainer in the amount of $8,750 per quarter (and pro-rated for partial quarters) due at the end of each calendar quarter. The retainer will give the Company access to the Advisor’s Services for up to 15 hours per quarter. In addition, the Parties agree that notwithstanding their contrary terms, with respect to those outstanding options to purchase shares of the Company’s common stock held by Advisor on the Effective Date, which options are set forth on Exhibit A to this Agreement, Advisor’s service under this Agreement shall constitute continued service to the Company such that # with respect to the option to purchase 15,000 shares of the Company’s common stock granted to Advisor on June 13, 2019, such option will continue to vest during the Term (as defined below), and # with respect to all such outstanding options, such options will remain exercisable during the Term and the post-termination exercise period of such options will not commence until the expiration of the Term. For the avoidance of doubt, effective as of the Effective Date, Advisor will no longer be eligible to receive compensation for service on the Board under the Company’s Non-Employee Director Compensation program.

Compensation. In consideration of Consultant’s performance of the Services, the Company shall pay Consultant at a rate of $23,333.00 for the first month of engagement and then $20,000.00 per month thereafter for the Services rendered by Consultant during the term of this Agreement. In addition to the forgoing, Consultant will be eligible for consideration to receive a bonus or portion of a bonus for 2020 performance for Consultant’s past contributions as an employee of the Company. At their sole discretion, the Compensation Committee of the Board of Directors will assess payout levels based on the Company’s performance against 2020 objectives and will make a recommendation accordingly. Furthermore, the Compensation Committee of the Board of Directors will consider additional incentive remuneration in stock or cash for the Consultant’s role in achieving key milestones such as (but not limited to) FDA clearance for PoNS for MS, TGA clearance for PoNS, Health Canada licenses for additional indications, or adoption by Helius of license to commercialize ENT/DG technology.

Compensation. In consideration of satisfactorily performing the Services, Company will pay to Consultant the fees on the schedule specified in Exhibit A hereto (“Fees”). Company will reimburse reasonable out-of-pocket expenses, if any, incurred by Consultant in the performance of the Services provided such are pre-approved in writing by Company (“Authorized Expenses”) (Fees and Authorized Expenses, collectively, the “Compensation”). The Compensation shall be Consultant’s sole remuneration unless the parties agree otherwise in writing. Consultant shall submit invoices to Company on a monthly basis for all Services provided and Authorized Expenses incurred during the preceding month. Each invoice shall include a detailed description of the Services performed delineated by project or task, as applicable, and a detailed description of the Authorized Expenses with all required receipts. All invoices must be sent to: [[Email]]. Payment terms are net thirty (30) days. Consultant understands that Company will report Consultant’s compensation and reimbursed expenses under this Agreement to the extent Company, in its sole opinion, believes that it is required to do so by applicable laws or regulations.